Filippo Spriano

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 9

Top Topics

Histone Deacetylase

Diffusion Weighted

Drug Administration

Top Venues

Molecular cancer therapeutics

Exploration of targeted anti-tumor therapy

Cancer research communications

This page only lists publications with an associated author ORCID identifier.

Publications

Francesca Zammarchi, Karin E Havenith, Nikoleta Sachini, Narinder Janghra, Simon Chivers, Esohe Idusogie, Eugenio Gaudio, Chiara Tarantelli, Francois Bertelli, Kathleen Santos, Peter Tyrer, Simon Corbett, Filippo Spriano, Gaetanina Golino, Luciano Cascione, Francesco Bertoni, John A Hartley, Patrick H van Berkel
ADCT-602, a novel PBD dimer-containing antibody-drug conjugate for treating CD22-positive hematological malignancies. Molecular cancer therapeutics (2024)
Francesca Zammarchi, Karin E Havenith, Nikoleta Sachini, Narinder Janghra, Simon Chivers, Esohe Idusogie, Eugenio Gaudio, Chiara Tarantelli, Francois Bertelli, Kathleen Santos, Peter Tyrer, Simon Corbett, Filippo Spriano, Gaetanina Golino, Luciano Cascione, Francesco Bertoni, John A Hartley, Patrick H van Berkel
ADCT-602, a Novel PBD Dimer-containing Antibody-Drug Conjugate for Treating CD22-positive Hematologic Malignancies. Molecular cancer therapeutics 23 (4) (2024)
Francesca Zammarchi, Karin E Havenith, Nikoleta Sachini, Narinder Janghra, Simon Chivers, Esohe Idusogie, Eugenio Gaudio, Chiara Tarantelli, Francois Bertelli, Kathleen Santos, Peter Tyrer, Simon Corbett, Filippo Spriano, Gaetanina Golino, Luciano Cascione, Francesco Bertoni, John A Hartley, Patrick H van Berkel
ADCT-602, a Novel PBD Dimer-containing Antibody-Drug Conjugate for Treating CD22-positive Hematologic Malignancies. Molecular cancer therapeutics 23 (4) (2024)
Alberto J Arribas, Sara Napoli, Luciano Cascione, Laura Barnabei, Giulio Sartori, Eleonora Cannas, Eugenio Gaudio, Chiara Tarantelli, Afua Adjeiwaa Mensah, Filippo Spriano, Antonella Zucchetto, Francesca Maria Rossi, Andrea Rinaldi, Manuel Castro de Moura, Sandra Jovic, Roberta Bordone Pittau, Anastasios Stathis, Georg Stussi, Valter Gattei, Jennifer R Brown, Manel Esteller, Emanuele Zucca, Davide Rossi, Francesco Bertoni
ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms. Molecular cancer therapeutics (2023)
Alberto J Arribas, Sara Napoli, Luciano Cascione, Laura Barnabei, Giulio Sartori, Eleonora Cannas, Eugenio Gaudio, Chiara Tarantelli, Afua Adjeiwaa Mensah, Filippo Spriano, Antonella Zucchetto, Francesca Maria Rossi, Andrea Rinaldi, Manuel Castro de Moura, Sandra Jovic, Roberta Bordone Pittau, Anastasios Stathis, Georg Stussi, Valter Gattei, Jennifer R Brown, Manel Esteller, Emanuele Zucca, Davide Rossi, Francesco Bertoni
ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms. bioRxiv : the preprint server for biology (2023)
Zoe Johnson, Chiara Tarantelli, Elisa Civanelli, Luciano Cascione, Filippo Spriano, Amy Fraser, Pritom Shah, Tyzoon Nomanbhoy, Sara Napoli, Andrea Rinaldi, Karolina Niewola-Staszkowska, Michael Lahn, Dominique Perrin, Mathias Wenes, Denis Migliorini, Francesco Bertoni, Lars van der Veen, Giusy Di Conza
IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. Cancer research communications 3 (4) (2023)
Marilia Barreca, Noemie Lang, Chiara Tarantelli, Filippo Spriano, Paola Barraja, Francesco Bertoni
Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidences. Exploration of targeted anti-tumor therapy 3 (6) (2022)
Marilia Barreca, Noemie Lang, Chiara Tarantelli, Filippo Spriano, Paola Barraja, Francesco Bertoni
Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidences. Exploration of targeted anti-tumor therapy 3 (6) (2022)
Afua Adjeiwaa Mensah, Filippo Spriano, Giulio Sartori, Valdemar Priebe, Luciano Cascione, Eugenio Gaudio, Chiara Tarantelli, Elisa Civanelli, Luca Aresu, Andrea Rinaldi, Giovanna Damia, Emanuela Lovati, Emanuele Zucca, Anastasios Stathis, Claudio Pietra, Francesco Bertoni
Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors. Blood advances 5 (10) (2021)